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Abstract
A high expression of short and immature O-glycans is one of the prominent features of breast cancer cells, which
would be attributed to the upregulated expression of glycosyltransferases. Therefore, a detailed elucidation of glyco-
syltransferases and their substrate(s) may improve our understandings for their roles in mammary carcinogenesis. Here
we report that overexpression of polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6), a glycosyltransferase
involved in the initial step of O-glycosylation, has transformational potentials through disruptive acinar morphogenesis
and cellular changes similar to epithelial-to-mesenchymal transition in normalmammary epithelial cell, MCF10A. As one
of the critical O-glycan substrates, we identified fibronectin that was O-glycosylated in vivo and thereby stabilized by
GALNT6. Because knockdown of fibronectin abrogated the disruptive proliferation caused by introduction of GALNT6
into epithelial cells, our findings suggest that GALNT6-fibronectin pathway should be a critical component for breast
cancer development and progression.
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Introduction
Alterations in O-type glycosylation of breast cancer cells induce diverse
biologic and pathologic consequences influencing growth and survival
of the cells and their ability for invasion and metastasis [1]. Accumu-
lating evidences have shown that aberrant expression of glycosyltrans-
ferases confers the altered O-glycan structures in breast cancer cells
[2,3]. In this regard, we previously characterized oncogenic roles of
GALNT6 that was upregulated exclusively in breast cancer cells and
regulated cell proliferation and cytoskeleton structure [4]. In accor-
dance to biologic relevance, GALNT6 expression was related with
poor prognosis of breast cancer patients, indicating its application as
a molecular marker for risk of cancer metastasis [5]. However, the
molecular mechanism of how GALNT6 contributes to breast malig-
nancy by enhancing the O-glycosylation remains unclear.
The three-dimensional culture of MCF10A mammary epithelial
cells was developed to assess oncogenic ability by monitoring the dis-
ruption of well-ordered architecture of mammary gland, which is re-
garded as an early aspect of mammary carcinogenesis [6]. Under the
three-dimensional culture conditions, MCF10A cells form the acinar
structure composed of a monolayer of polarized cells, but the well-
organized architecture was disrupted by the introduction of certain
cancer-related genes [7–9]. In addition to investigating cell morpho-
genesis, the three-dimensional culture-basedmonitoring system provides
more accurate physiological conditions to assess oncogenic functions
related to invasive behavior and epithelial-to-mesenchymal transition
(EMT) [7].
In this study, we generated GALNT6-expressing MCF10A stable
transfectants and clarified transformational potentials of GALNT6
by the three-dimensional culture method in the aspects of disruption
of acinar structure formation as well as EMT-like cellular alterations.
Abbreviations: EMT, epithelial-to-mesenchymal transition; GALNT6, polypeptide
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Address all correspondence to: Yusuke Nakamura, MD, PhD, Laboratory of Molecular
Medicine, Human Genome Center, Institute of Medical Science, The University of
Tokyo, 4-6-1 Shirokanedai, Minato-Ku, Tokyo 108-8639, Japan.
E-mail: yusuke@ims.u-tokyo.ac.jp
1No potential conflict of interest was disclosed.
2This article refers to supplementary materials, which are designated by Figures W1
and W2 and are available online at www.neoplasia.com.
Received 11 October 2010; Revised 6 January 2011; Accepted 6 January 2011
Copyright © 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00
DOI 10.1593/neo.101440
www.neoplasia.com
Volume 13 Number 4 April 2011 pp. 320–326 320
Materials and Methods
Cell Lines
Human breast cancer cell lines (T47D and HCC1500) and an im-
mortalized breast epithelial cell line (MCF10A) were purchased from
American Type Culture Collection (Rockville, MD) and Cambrex
Bioscience (Walkersville, MD), respectively. Detailed cell culture and
test methods were previously described [4]. The cell viability was as-
sessed by Cell Counting Kit 8 (Dojindo, Kumamoto, Japan).
Three-dimensional Cell Culture with MCF10A-GALNT6
Stable Transfectants
Each of the pCAGGS-HAc expression vectors of mock (no in-
sert), GALNT6 wild-type (WT), and inactivated GALNT6 mu-
tant (H271D) was transfected into MCF10A cells using FuGENE6
transfection reagent (Roche, Basel, Switzerland), as previously described
[4]. Then, the positive clones were selected under incubation with cul-
ture medium containing 0.4 mg/ml of Geneticin (Invitrogen, Carlsbad,
CA) and validated by Western blot analysis and immunocytochemical
staining. The cells were seeded on the growth factor–reduced Matrigel
(BD Biosciences, San Jose, CA) and maintained in mammary epithelial
cell medium media (Cambrex Bioscience) with 2% of the Matrigel [6].
Each size of cell colonies was quantified by ImageJ software by National
Institutes of Health (Bethesda, MD) [10].
Western Blots and Immunocytochemical Staining
SDS-PAGE, immunoprecipitation, and immunocytochemical
staining were performed as described previously [4], with anti–E-
or N-cadherins (BD Biosciences), anti-fibronectin (Santa Cruz Biotech-
nology, Santa Cruz, CA), anti–β-actin (Sigma-Aldrich, St Louis, MO),
anti–integrin α6 (Chemicon, Billerica, MA), and anti–active caspase-3
(Abcam, Cambridge, UK) antibodies. The cytoskeleton structure was
visualized by staining with Alexa Fluor-488/594 phalloidins (Molecu-
lar Probe, Eugene, OR). The GalNAc (N -acetyl-α-D-galactosamine)–
conjugated glycoproteins were detected by Vicia villosa (VVA) lectin
(Vector, Burlingame, CA) with or without incubation with recombi-
nant GALNT6 proteins in vitro [4].
Knockdown Experiments
To deplete endogenous expression of fibronectin, we introduced
a synthesized oligo-duplex small interfering RNA (siRNA) against the
FN1 gene (5′-AAGTGGTCCTGTCGAAGTATT-3′) into MCF10A-
GALNT6 stable transfectants once a week [11]. We used si-GALNT6
(5′-GAGAAAUCCUUCGGUGACA-3′) to deplete endogenous
expression of GALNT6 and used si-EGFP (5′-GAGAAAUCCUUCG-
GUGACA-3′) as a control [4]. Semiquantitative reverse transcription–
polymerase chain reaction was performed as described previously [12].
The polymerase chain reaction primer sequences were 5′-CTGCAG-
TATATCCGCTTAGCC-3′ and 5′-TAAGTCCATGCAAAGGAGA-
CTAGC-3′ for ACTB and 5′GGAGTTGATTATACCATCACTG-3′
and 5′-TTTCTGTTTGATCTGGACCT-3′ for FN1 (GenBank
no. NM_002026).
Statistical Analysis
Statistical significance was examined by Student’s t test using R sta-
tistical package [13]. A difference of P < .05 was considered to be sta-
tistically significant.
Results
Breast Cancer Cells Express Multiple O-glycan Substrates
of GALNT6
MUC1 was one of important substrates of GALNT6 in breast can-
cer cells (T47D, MCF7, and SKBR3). However, our previous find-
ings indicated the presence of additional O-glycan substrates that
would be O-glycosylated by GALNT6 [4]. Indeed, VVA-lectin West-
ern blot analysis indicated the presence of multiple substrates whose
O-glycosylations were diminished by knockdown of GALNT6 (Fig-
ure 1A, lane 1 vs 4 ). The glycosylations of these candidate bands were
restored by in vitro incubation with recombinant WT GALNT6 pro-
tein (Figure 1A, lane 4 vs 5 ). This result was in concordance with our
previous speculation that GALNT6 might have additional functions
through O-glycosylation of unidentified substrates [4].
Overexpression of GALNT6 Induces EMT-like
Morphologic Alterations
To investigate unidentified substrates of GALNT6, we generated
transfectants stably expressing WT- or enzyme-dead- (H271D)
GALNT6 in MCF10A cell that expressed a very low level of GALNT6
and MUC1 proteins [4]. In contrast to T47D cells (Figure 1A), VVA-
lectin analysis recognized only a few bands that showed intensity en-
hancement by overexpression of GALNT6 (Figure 1B, left) and we
observed no effect on the proliferation of MCF10A cells (Figure 1B,
right). It might be due to the lower expression of some GALNT6 sub-
strates in MCF10A cells. However, we observed significant morphologic
changes from epithelial-like cells to mesenchymal-like cells by intro-
duction of WT-GALNT6 (Figure 1C). Because such EMT-like changes
have been strongly implicated in relation to cancer progression with
abolished cell adhesion [14], we further performedWestern blot analysis
using the antibody to E-cadherin that is the representative cell adhesion
molecule and an epithelial cell maker and found that E-cadherin expres-
sion was reduced by the overexpression of WT-GALNT6. However,
E-cadherin expression level was elevated by H271D-GALNT6 in-
duction than transfection of mock control, indicating a dominant nega-
tive effect of H271D-GALNT6 to the weakly expressed endogenous
GALNT6 protein (Figure 1D, left). Interestingly, a mesenchymal cell
marker, N-cadherin was inversely correlated with the expression levels
of E-cadherin (Figure 1D, right) as known as “cadherin switching” that
was supposed to be regulated in transcriptional levels [15]. Hence, it is
likely that substrates of GALNT6 and their downstream targets might
affect such a competitive transcription of two cadherins. In addition,
the reduction of E-cadherin was also observed in HCC1500 breast can-
cer cells, which showed a low level of GALNT6, by the overexpression
of GALNT6 (Figure W1).
Overexpression of GALNT6 Disrupts Acinar Formation of
MCF10A Cells in Three-dimensional Culture
The three-dimensional cell culture enabled us to monitor cell
morphogenesis in a relatively physiological condition compared with
the conventional two-dimensional cell culture. Hence, we performed
three-dimensional cell culture of MCF10A-GALNT6 stable cells and
observed irregular and invasive proliferation of these cells into Matrigel
matrix after 10 days of incubation (Figure 2A). Subsequently, we quan-
tified each acinar size and found that the disruptive proliferation of
MCF10A cells was induced by the overexpression of WT-GALNT6,
although it was not observed in MCF10A-H271D-GALNT6 stable
cells (Figure 2B). In addition, we performed immunocytochemical
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staining and detected reduction of E-cadherin protein in the cell-cell
contact region in MCF10A-WT-GALNT6 stable cells (Figure 2C ),
but E-cadherin was augmented by H271D-GALNT6 in concordance
with the results of Western analysis as shown in Figure 1D.
It has been suggested that disruption of the acinar morphogenesis
usually coincides with loss of cell polarity and antiapoptotic activity
of inner cells [6,16]. Therefore, we examined a cell polarity marker
(integrin α6) and a cell apoptosis marker (active caspase-3) by immuno-
cytochemistry. Expectedly, we confirmed that WT-GALNT6 induced
loss of the cell polarity (Figure 2D) and facilitated the survival of inner
cells (Figure W2). Because these morphologic alterations were abro-
gated by the enzyme-dead mutant (H271D), our findings strongly
Figure 1. Overexpression of GALNT6 in MCF10A cell. (A) Each of the T47D cell lysates from si-EGFP and si-GALNT6 was incubated with
recombinant GALNT6 proteins (WT and H271D) before VVA-lectin Western blot analysis. (B) Overexpression of WT-GALNT6 in MCF10A
cell augmented a few of the O-glycan bands (left) but showed no influence on the cell proliferation (right). Arrows indicate candidate
O-glycan substrates of GALNT6 (A, B). Overexpression of WT-GALNT6 induced EMT-like cell morphologic changes (C) that were vali-
dated by Western blots with EMT markers, E- and N-cadherins (D). The representative images of epithelial and mesenchymal cells (C)
were modified from Lee et al. [14]. Scale bars, 100 μm.
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suggested that transformational potentials of GALNT6 should be due
to its O-glycosyltransferase activity.
Fibronectin Is O-glycosylated and Stabilized by GALNT6
To further understand the biologic function of GALNT6, we
focused on fibronectin as a substrate because it contained candi-
date sites of glycosylation by GALNT6 [17] and was reported to
promote MCF10A cell proliferation in three-dimensional culture
[18]. To examine in vivo glycosylation of fibronectin by GALNT6,
we immunoprecipitated the endogenous fibronectin protein from
MCF10A-GALNT6 stable cells and detected a glycosylated band of
the fibronectin protein by VVA-lectin Western blot (Figure 3A). Be-
cause the O-glycosylation was considered to be important to maintain
protein stability [4,19,20], we next examined the expression of fibro-
nectin at the transcript and protein levels. The result revealed that there
was no difference in the transcript levels among WT-GALNT6 cells,
H271D-GALNT6 cells, and mock cells but that the fibronectin pro-
tein was significantly more abundant in WT-GALNT6 cells than
mock and H271D-GALNT6 cells (Figure 3B). This suggested that
GALNT6 might contribute to maintain protein stability of fibronectin
through O-glycosylation. In addition, this speculation was further vali-
dated by the reduction of the fibronectin protein in the GALNT6-
depleted T47D cells (Figure 3C ).
Fibronectin Mediates the Acinar Disruption That Was
Induced by GALNT6
According to previous findings for fibronectin in three-dimensional
cultured MCF10A cells [18], we speculated that fibronectin could be
a critical downstream molecule of GALNT6 and be indispensable for
the disruptive proliferation of the MCF10A stable cells. When the
fibronectin was depleted by transfections with siRNA, the irregular
shape morphology and aberrant proliferation of MCF10A cells were
diminished as observed in 3D-cell culture (Figure 4A). After 3 weeks
of incubation in three-dimensional culture, we quantified each acinar
size and found that the knockdown of fibronectin significantly abol-
ished the effect of WT-GALNT6 overexpression that had led to disrup-
tion of acinar structure (Student’s t test, P = 2.1 × 10−7; Figure 4B).
Moreover, knockdown of fibronectin restored E-cadherin protein
(Figure 4C ) that had been reduced by WT-GALNT6 (Figure 2C ).
These findings supported our speculation that fibronectin, as one of
Figure 2. Three-dimensional cell culture of MCF10A-GALNT6 stable transfectants. (A) Disruptive and invasive proliferation of MCF10A
cells was observed from WT-GALNT6 stable transfectants cultured in the Matrigel matrix after incubating for 10 days. (B) Quantification
and statistical analysis for acinar sizes (n > 50). *P = 9.6 × 10−5. **P = 4.4 × 10−5. (C) Reduction of E-cadherin by overexpression of
WT-GALNT6. (D) Staining of integrin α6 around the outer region of the acinar was abrogated (arrow) by the overexpression of WT-GALNT6,
which indicated loss of cell polarity. Scale bars, 100 μm (A); 20 μm (C, D).
Neoplasia Vol. 13, No. 4, 2011 GALNT6 Induces EMT by Stabilizing Fibronectin Park et al. 323
the O-glycan substrates of GALNT6, would be a critical mediator that
conferred transformational potentials to MCF10A cells.
Discussion
Despite that the short and immature O-glycans of breast cancer cells
have been known for a long time, the molecular characteristics of
O-type glycosylation make it difficult to be analyzed. For instance,
neither amino acid consensus sequence nor universal enzyme for
the release of O-glycans has been identified [21]. Because O-type
glycosylation is initiated by glycosyltransferases belonging to the
GALNT family [22], mutual examination of both GALNT enzyme
and its direct substrate(s) may contribute to our understanding of aber-
rant O-glycosylations in carcinogenesis. Indeed, accumulating studies
have elucidated cellular functions of O-glycosylation throughout iden-
tification of deregulated GALNT enzymes and their O-glycan sub-
strates [23,24].
We previously identified GALNT6 as a novel therapeutic target for
breast cancer. We also characterized GALNT6’s roles in breast cancer
cell by identification of a directO-glycan substrate, MUC1 [4]. Because
the enzyme activity of GALNT6 was critical to modulate oncogenic
Figure 3. GALNT6 O-glycosylates and stabilizes fibronectin. (A) In vivo O-glycosylation of fibronectin by WT-GALNT6. From each of the
MCF10A-GALNT6 stable transfectants, the endogenous fibronectin protein (arrow) was immunoprecipitated and blotted with VVA-lectin.
Then, the membrane was stripped and immunoblotted with an anti-fibronectin monoclonal antibody. A posttranscriptional regulation of
fibronectin protein was validated by Western blot analysis (upper) and reverse transcription–polymerase chain reaction (lower) in MCF10A
cells overexpressing GALNT6 (B) or in T47D cells depleted with GALNT6 (C).
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Figure 4. GALNT6-induced disruptive proliferation of MCF10A cell is dependent on fibronectin. (A) Knockdown of fibronectin abolished
the disruptive and invasive proliferation of MCF10A-GALNT6 stable transfectants. The cells were incubated for 3 weeks with repeated trans-
fections with siRNA. (B) Knockdown of fibronectin was validated in the MCF10A-GALNT6 stable cells transfected with siRNA for 1 week.
Quantification and statistical analysis were conducted for acinar sizes (n > 100). *P = 2.1 × 10−7. (C) Reduction of E-cadherin by over-
expressed WT-GALNT6 (white arrow) was restored in the fibronectin-depleted WT-GALNT6 stable transfectants (yellow arrow). Scale bars,
100 μm (A); 20 μm (C).
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pathways of MUC1, high-throughput screening of GALNT6 inhibi-
tor was expected to lead to the development of novel anticancer drugs.
This idea is in concordance with recent approaches for cancer ther-
apy by means of inhibiting cancer-specific glycosylations [25]. How-
ever, because different isoforms of GALNT family glycosylate diverse
O-glycan substrates [21], intensive characterization in both glycosyl-
transferase and downstream should be preceded before screening of
therapeutic chemicals.
In this study, we identified fibronectin, which is known to be de-
graded intracellularly after endocytosis [26], as an important in vivo
substrate of GALNT6. Our data reported here imply that GALNT6-
induced O-glycosylation may interfere with this degradation process
and stabilize fibronectin. Although the molecular mechanism that
links between stabilization of fibronectin and reduction of E-cadherin
is still unclear, we suggest that the upregulated expression of GALNT6
enhances transformational potentials ofmammary epithelial cells through
O-glycosylation of fibronectin thatmight facilitate disruptive and invasive
cell proliferation in vivo. However, because breast cancer cells may have
another O-glycan substrates of GALNT6 (Figure 1A), identifying more
substrates and related downstream molecules for the comprehensive
understanding of GALNT6’s role in breast cancer is warranted.
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Figure W1. Reduction of E-cadherin by overexpression of WT-GALNT6. Reduction of E-cadherin was observed in HCC1500 breast cancer
cells by overexpression of WT-GALNT6 (yellow arrows). However, that of H271D-GALNT6 (white arrows) had no influence on E-cadherin.
Red arrows indicate reduced staining of E-cadherin in the cell-cell adhesion region, whichwas observed in the cells expressingWT-GALNT6.
Figure W2. Immunocytochemical staining of MCF10A-GALNT6 stable transfectants in three-dimensional cell culture. Each of the
MCF10A-GALNT6 stable transfectants was immunostained with a cell apoptosis marker, active caspase-3. Fewer apoptotic cells were
observed in the center of the acinar structure (arrow) by overexpression of WT-GALNT6.
